Improving Lentiviral Vector Downstream Processing Workflows

Article inspired by a Tapas and TechTalks digital event. Fast Trak Centre for Advanced Therapeutic Cell Technologies (CATCT) team members shared insights from customer collaborations.

Lentiviral vectors (LVV) are a common vehicle to deliver genetic material in CAR T cell therapy and gene therapy applications. Production methods have been developed by adapting technologies from the bioprocessing sector. However, these downstream workflows are long, require substantial manual labor, and suffer from low yields of infectious virus. In this article we discuss process development pain points of a modern workflow and ways to address them. We look at new technologies that may be applicable to cell and gene therapy as well as older technologies that have proven very valuable in bioprocessing and can be adapted to serve similar functions in cell and gene manufacturing.